RxDoctor Payments Data

David Hoefer, MD

Family Medicine · Cypress, TXNPI 1861480592

Payments from drug & device makers

$5,011in general payments, 2019–2025

Across 309 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$648
  • Boehringer Ingelheim$461
  • Amarin Pharma, Inc.$240
  • Lilly USA, LLC$239
  • Pfizer$229
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,996100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,011 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$74,061
Medicare patients
446
Services billed
838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$73,223
JardianceEmpagliflozin29$35,514
MounjaroTirzepatide15$19,254
TrulicityDulaglutide12$15,350
EliquisApixaban14$11,823
Venlafaxine Hcl ErVenlafaxine Hcl18$3,385
SynthroidLevothyroxine Sodium34$2,208
Rosuvastatin Calcium105$1,783
Levothyroxine Sodium177$1,546
PaxlovidNirmatrelvir/Ritonavir14$1,429
Gabapentin63$1,249
Losartan Potassium97$1,044
Metoprolol Succinate54$996
Atorvastatin Calcium149$874
Albuterol Sulfate HfaAlbuterol Sulfate34$817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,111$73,22373 claims
Boehringer IngelheimJardiance$461$35,51429 claims
Lilly USA, LLCMounjaro, Trulicity$239$34,60427 claims
PfizerEliquis, Paxlovid$229$13,25328 claims
AbbVieSynthroid$648$2,20834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →